Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linda Mileshkin

Showing results (151-160 of 174) with videos related to

Pageof 18
Sort By:
International Journal of Radiation Oncology, Biology, Physics|October 5, 2021
Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation TherapyBastiaan G Wortman, Cathalijne C B Post, Melanie E Powell, et al.
Journal of the National Cancer Institute|March 11, 2021
Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial CancerCathalijne C B Post, Ellen Stelloo, Vincent T H B M Smit, et al.
JCO Precision Oncology|February 1, 2022
Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE StudyOlga Kondrashova, Gwo-Yaw Ho, George Au-Yeung, et al.
Nature Communications|May 28, 2020
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancerElaine Sanij, Katherine M Hannan, Jiachen Xuan, et al.
BMC Cancer|January 29, 2025
Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary originAnna Ugalde, Richard W Tothill, Stephen Quinn, et al.
The Lancet. Oncology|August 30, 2024
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroupCarien L Creutzberg, Jae-Weon Kim, Gemma Eminowicz, et al.
Obstetrical & Gynecological Survey|December 30, 2025
Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
The Lancet. Oncology|September 8, 2025
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
The Lancet. Oncology|August 31, 2016
Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysisSebastian Moran, Anna Martínez-Cardús, Sergi Sayols, et al.
The Journal of Pathology|October 26, 2022
A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primaryAtara Posner, Owen Wj Prall, Tharani Sivakumaran, et al.
Pageof 18

Showing results (151-160 of 174) with videos related to

Sort By:
Pageof 18
International Journal of Radiation Oncology, Biology, Physics|October 5, 2021
Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation TherapyBastiaan G Wortman, Cathalijne C B Post, Melanie E Powell, et al.
Journal of the National Cancer Institute|March 11, 2021
Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial CancerCathalijne C B Post, Ellen Stelloo, Vincent T H B M Smit, et al.
JCO Precision Oncology|February 1, 2022
Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE StudyOlga Kondrashova, Gwo-Yaw Ho, George Au-Yeung, et al.
Nature Communications|May 28, 2020
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancerElaine Sanij, Katherine M Hannan, Jiachen Xuan, et al.
BMC Cancer|January 29, 2025
Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary originAnna Ugalde, Richard W Tothill, Stephen Quinn, et al.
The Lancet. Oncology|August 30, 2024
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroupCarien L Creutzberg, Jae-Weon Kim, Gemma Eminowicz, et al.
Obstetrical & Gynecological Survey|December 30, 2025
Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
The Lancet. Oncology|September 8, 2025
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
The Lancet. Oncology|August 31, 2016
Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysisSebastian Moran, Anna Martínez-Cardús, Sergi Sayols, et al.
The Journal of Pathology|October 26, 2022
A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primaryAtara Posner, Owen Wj Prall, Tharani Sivakumaran, et al.
Pageof 18